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Abstract
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Context—Approximately 60% to 100% of women with breast cancer experience at least one
menopausal-related symptom. Little is known about associations between menopausal status and
symptoms in women 12 months after breast cancer surgery.
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Objective—Purpose of this study was to evaluate for differences in occurrence, severity, and
distress of symptoms between pre- and post-menopausal women 12 months after breast cancer
surgery.
Methods—Women with breast cancer (n=327) completed the Menopausal Symptoms Scale, that
evaluated the occurrence, severity, and distress of 46 common menopausal-related symptoms.
Regression analyses were used to evaluate for between group differences in the seven symptoms
that occurred in ≥30% of the sample (i.e., hot flashes, night sweats, depression, daytime sweats,
joint pain or stiffness, wake during the night, numbness or tingling).
Results—Of the 327 breast cancer patients who completed the 12-month assessment, 35.2%
were premenopausal and 64.8% were postmenopausal prior to surgery. In the conditional models,
when significant interactions were found, the differences in symptom occurrence rates between
pre- and postmenopausal patients depended on their age.
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Conclusions—Regardless of menopausal status, women reported relatively high occurrence
rates for several menopausal symptoms. Associations between symptom occurrence rates and
menopausal status depended on the patient’s age.
Implications for Practice—During the development of a survivorship care plan, clinicians
need assess symptom burden within the context of a woman’s menopausal status and salient
demographic and clinical characteristics. This approach will assist with the prescription of more
effective interventions.
Keywords
symptoms; premenopausal; postmenopausal; breast cancer; surgery
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INTRODUCTION
Between 65% and 100% of women with breast cancer experience at least one treatmentinduced, menopausal-related symptom.1,2 These symptoms include: sleep disturbance,
musculoskeletal pain, mood changes, vasomotor symptoms, sexual dysfunction, vaginal
dryness and atrophy, cognitive impairment, headaches, weight gain, and fatigue.3,4 These
menopausal-related symptoms are some of the most common and distressing side effects of
breast cancer treatment.2,5 Moreover, because of abrupt changes in sex steroid hormones,
these symptoms are often more frequent and severe than those experienced during a natural
menopausal transition.6 For premenopausal women, this unexpected exacerbation of
symptoms can have a negative impact on their quality of life (QOL).6,7

Author Manuscript

The occurrence, severity, and distress from these menopausal-related symptoms vary based
on a woman’s menopausal status;8–10 age;4,11 type of cancer treatment (i.e., chemotherapy
(CTX), endocrine therapy (ET));12,13 and time since completion of treatment; as well as
demographic, health and illness, and psychosocial factors.12 For example, following breast
cancer treatment, compared to postmenopausal patients, women who were premenopausal at
diagnosis reported more severe vasomotor symptoms,14 sexual dysfunction,15 and sleep
disturbances.14 In addition, in another study,16 the highest menopausal-related symptom
burden was reported in the first six months after the completion of primary treatment.
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While, the impact of menopausal-related symptoms is well documented,1,2,5,12,17–19 little is
known about differences in the occurrence, severity, and distress of these symptoms between
premenopausal and postmenopausal women one year after breast cancer surgery. The
majority of these studies compared differences in the symptom experience of older versus
younger women;4,11,20 younger women who did or did not experience treatment-induced
menopause;1,2,10 and/or specific types of treatment (i.e., CTX, tamoxifen, aromatase
inhibitors (AIs)).12,13,21–24 Moreover, the majority of these studies evaluated a single
symptom; a single dimension of the symptom experience; included women several years
after a breast cancer diagnosis; and/or did not evaluate the impact of menopausal status on
differences in patients’ symptom experiences. (for reviews see1, 3, 10) In fact, to our
knowledge, only five studies reported on differences in menopausal-related symptoms
between pre- and postmenopausal women after primary breast cancer treatment.8,9,14,15,25
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These five studies evaluated for associations between pre-diagnosis menopausal status and
symptom occurrence8,9,25 or severity14,15 in women who had received adjuvant CTX and/or
ET. Two longitudinal studies evaluated symptom severity before and immediately after
CTX.28,29 Three cross-sectional studies evaluated menopausal symptom occurrence six
months21 to several years7,27 after diagnosis. Compared to postmenopausal patients,
premenopausal women reported higher occurrence rates of hot flashes, night sweats,8,9,25
vaginal dryness, and libido reduction.8 In one study,8 while two-thirds of the menopausalrelated symptoms were reported as severe by premenopausal women, differences in severity
scores between pre- and postmenopausal women were not evaluated.

Author Manuscript

Findings from these five studies provide preliminary evidence of differences in the
occurrence8,9,25 and severity14,15 of menopausal-related symptoms based on pre-diagnosis
menopausal status. However, a number of limitations warrant consideration. These studies
evaluated only a single symptom14 and/or one dimension of the symptom experience.
8,9,14,15,25 Two studies did not include relevant covariates such as body mass index (BMI) in
their analysis.8,25 In two studies, the assessments were done either several years after the
cancer diagnosis25 or the time since diagnosis was not reported.8 In addition, in two studies,
14,15 the sample sizes of premenopausal women were relatively small. If differences were
found in the symptom experience of pre- versus postmenopausal women after surgery, this
information could be used to guide symptom management interventions.
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Given the paucity of research on the association between menopausal status prior to surgery
and menopausal-related symptoms after primary breast cancer treatment, the purpose of this
study was to evaluate for differences in multiple dimensions of the symptom experience (i.e.,
occurrence, severity, distress) between pre- and postmenopausal women one year after breast
cancer surgery. We hypothesized that both groups of women would report the co-occurrence
of multiple menopausal-related symptoms. In addition, we hypothesized that compared to
postmenopausal women, women who were premenopausal at diagnosis would report higher
occurrence rates of and severity and distress ratings for vasomotor symptoms (i.e., hot
flashes, night sweats, daytime sweats).
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METHODS
The methods for the larger descriptive, longitudinal study that evaluated neuropathic pain
and lymphedema in women who underwent breast cancer surgery are described in detail
elsewhere.26–30 In brief, women were recruited from seven Breast Cancer Centers in
Northern California. Women were eligible if they: were ≥18 years of age; were scheduled
for unilateral breast cancer surgery; were able to read, write, and understand English; agreed
to participate; and provided written informed consent. Patients were excluded if they had
bilateral breast surgery and/or had distant metastases at the time of diagnosis.
Instruments
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Patients completed a demographic questionnaire, the Karnofsky Performance Status (KPS)
scale,31 and the Self-Administered Comorbidity Questionnaire (SCQ).32 Menopausal status
was determined by the patient’s response (yes/no) at the time of study enrollment to the
question “Have you gone through menopause yet (stopped having your menstrual cycle)?”.
The Menopausal Symptoms Scale (MSS), that was modified from the Seattle Women’s
Health Study questionnaire,33 was used to evaluate the occurrence, severity, and distress of
46 menopausal-related symptoms. Women were asked to indicate whether they experienced
each symptom during the past week (i.e., symptom occurrence). If they experienced the
symptom, they were asked to rate its severity and distress. Symptom severity was rated on a
0 (‘none’) to 10 (‘intolerable’) numeric rating scale (NRS). Symptom distress was rated on a
0 (‘not at all distressing’) to 10 (‘very distressing’) NRS. The MSS has well established
validity and reliability.34
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Study Procedures
The study was approved by the Committee on Human Research at the University of
California, San Francisco and by the Institutional Review Boards at each of the study sites.
A clinician explained the study, determined the woman’s willingness to participate, and
introduced her to the research nurse. All patients provided written informed consent. Women
completed the enrollment questionnaire an average of four days prior to surgery. For the
current study, data from the KPS, SCQ, and MSS that were obtained one year after surgery
were analyzed. Medical records were reviewed for disease and treatment information.
Statistical Analysis
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Data were analyzed using SPSS Version 23 (IBM, Armonk, NY). Descriptive statistics and
frequency distributions were generated on sample characteristics and symptom occurrence
rates, severity scores, and distress scores. Using their self-reported status, women were
categorized into the premenopausal and postmenopausal groups at enrollment (i.e., prior to
surgery). Independent Student t-tests, Mann-Whitney U tests, Fisher Exact tests, and Chi
Square analyses were used to evaluate for differences in demographic and clinical
characteristics between the two menopausal groups. Characteristics that differed
significantly between the menopausal groups were considered for use as potential covariates
in the logistic and linear regression analyses.
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As part of the evaluation of between group differences, symptom occurrence rates were
generated for each symptom and mean scores for severity and distress ratings were
calculated for patients who reported a symptom. Unadjusted and adjusted logistic regression
analyses were used to evaluate for between group differences in symptom occurrence rates.
For symptoms that occurred in ≥30% of the total sample, unadjusted and adjusted linear
regression analyses were used to evaluate for between group differences in symptom severity
and distress scores. First, menopausal status was entered into the regression analysis
(unadjusted model). Then, characteristics that were found to be significantly different
between the two menopausal groups and identified as potential covariates were added into
the model along with menopausal status (adjusted model). Finally, the interaction between
age and menopausal status group was evaluated. If the age by menopausal status group
interaction was statistically significant, an adjusted stratified analysis was done for
premenopausal and postmenopausal women.35 The stratified analyses were done because the
interaction term was significant, but the sample size was too small to generate stable
combined estimates. A p-value of <.05 was considered statistically significant.
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RESULTS
Differences in demographic characteristics
Of the 327 women with breast cancer who completed the 12-month assessment, 35.2% were
premenopausal and 64.8% were postmenopausal prior to surgery. Compared to
postmenopausal women, premenopausal women were significantly younger, were less likely
to live alone, and were more likely to be employed (Table 1).
Differences in clinical characteristics
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Compared to postmenopausal women, premenopausal women had a lower SCQ score. In
addition, a lower percentage of premenopausal women reported high blood pressure,
diabetes, ulcer, osteoarthritis, a prior hysterectomy, a prior oophorectomy, were on HRT
prior to surgery, and had external beam radiation therapy (RT) during the prior 12 months. A
higher percentage of premenopausal women had a mastectomy versus conservation surgery,
had breast reconstruction during the prior 12 months, received adjuvant CTX during the
prior 12 months, and had undergone genetic testing for BRCA1 and BRCA2 (Table 1).
Differences in symptom occurrence rates and total number of symptoms
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Occurrence rates for the 46 symptoms on the MSS and for the top ten occurring symptoms
are listed in the Supplementary Table 1 and in Table 2, respectively. No differences were
found in the total number of symptoms reported by premenopausal versus postmenopausal
women. The five symptoms with the highest occurrence rates in premenopausal women
were: wake during the night, hot flashes, fatigue or tiredness, difficulty falling asleep, and
night sweats. While wake during the night, fatigue or tiredness and hot flashes, were among
the 5 most common symptoms in the postmenopausal group, they reported two different
symptoms (i.e., joint pain or stiffness and waking too early).
Unadjusted and adjusted analyses of symptoms with higher occurrence rates
in premenopausal women—As shown in Table 3, in the unadjusted models,
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premenopausal patients reported higher occurrence rates for eating more than usual, skin
breakout/acne, hostility, weight gain, irritability, and lost sexual interest. In the multivariate
analyses, after adjusting for nine covariates, no differences in these symptoms’ occurrence
rates were found between the two menopausal groups.
Unadjusted and adjusted analyses of symptoms with higher occurrence rates
in postmenopausal women—In the unadjusted and adjusted analyses, none of the
symptom occurrence rates were significantly higher in the postmenopausal group.
Differences in occurrence rates for symptoms with interaction effects—As
shown in Table 4, in the unadjusted models, premenopausal women reported higher
occurrence rates for hot flashes, night sweats, depression, and daytime sweats.
Postmenopausal women reported higher occurrence rates for joint pain or stiffness.
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In the adjusted models that evaluated seven symptoms for which significant interactions
were found between age and menopausal status (i.e., hot flashes, night sweats, depression,
daytime sweats, joint pain or stiffness, wake during the night, numbness or tingling), the
differences in symptom occurrence rates between pre- and post-menopausal women
depended on their age. In the premenopausal group, as age increased, women were
significantly more likely to report depression and joint pain or stiffness. In the
postmenopausal group, as age increased, women were significantly less likely to report hot
flashes, night sweats, depression, daytime sweats, wake during the night, and numbness or
tingling.
Differences in symptom severity scores
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The severity scores for the 46 as well as for the ten symptoms with the highest mean severity
scores are listed in the Supplementary Table 1 and in Table 2, respectively. For
premenopausal women, the five symptoms with the highest severity scores were: cramps,
diarrhea, lost sexual interest, fatigue or tiredness, and mood swings. While lost sexual
interest and cramps were among the five most severe symptoms in the postmenopausal
group, they reported three different symptoms (i.e., abdominal bloating, vaginal dryness, hot
flashes).
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Unadjusted and adjusted analyses of symptoms with higher severity scores
in premenopausal women—As shown in Table 5, in the unadjusted models for
symptoms that occurred in >30.0% of the sample, premenopausal women reported higher
symptom severity scores for impatience and irritability. In the adjusted analysis,
premenopausal women reported higher symptom severity scores for fatigue.
Unadjusted and adjusted analyses of symptoms with higher severity scores
in postmenopausal women—In the unadjusted and adjusted analyses, none of the
severity scores were significantly higher in the postmenopausal group.
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The distress scores for the 46 symptoms, as well as for the ten symptoms with the highest
mean distress scores, are listed in the Supplementary Table 1 and in Table 2, respectively.
For premenopausal women, the five symptoms with the highest distress scores were: weight
gain, diarrhea, swollen hands/feet, hostility, and tearful/crying spells. While weight gain was
one of the five most distressing symptoms in the postmenopausal women, they reported four
different symptoms (i.e., lost sexual interest, cramps, abdominal bloating, eating more than
usual).
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Unadjusted and adjusted analyses of symptoms with higher distress scores
in premenopausal women—As shown in Table 5, in the unadjusted analyses for
symptoms that occurred in >30% of the sample, premenopausal women reported higher
distress scores for impatience. In the adjusted analyses, none of the distress scores were
significantly higher in premenopausal women.
Unadjusted and adjusted analyses of symptoms with higher distress scores
in postmenopausal women—In the unadjusted and adjusted analyses, none of the
symptom distress scores were significantly higher in the postmenopausal women.

DISCUSSION

Author Manuscript

This study is the first to describe associations between preoperative menopausal status and
symptom occurrence, severity, and distress in women one year after breast cancer surgery.
Consistent with previous studies,1,2,4,36 our first hypothesis was supported. All women,
regardless of menopausal status, reported an average of 11 co-occurring symptoms (range of
0 to 38). Our second a priori hypothesis was only partially supported. After accounting for
multiple demographic, clinical, and treatment characteristics, the relationship between
menopausal status and the occurrence rates for vasomotor symptoms was dependent on
women’s age. In terms of severity, fatigue was the only symptom that was more severe in
premenopausal women. Of note, no differences in symptom distress ratings were found
between the menopausal groups.
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Findings from this study have a number of clinical implications. For example, our findings
suggest that women who used HRT prior to their breast cancer diagnosis were two to three
times more likely to report vasomotor symptoms even one year after stopping the
medication. Therefore, previous use of HRT should be assessed as part of survivorship care.
Given the large number of symptoms and dimensions evaluated, the discussion will focus
primarily on significant differences in symptom dimensions found between pre- and
postmenopausal women and the interaction of age and menopausal status.
Symptom Occurrence
Differences in the occurrence of symptoms with interaction effects—One of the
strengths of this study is that for each of the symptoms, after controlling for clinically
meaningful characteristics, the interaction between menopausal status and age was
evaluated. For example, significant interactions were found between age and menopausal
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status for all three vasomotor symptoms (i.e., hot flashes, night and daytime sweats). While
this specific interaction was not reported previously, relative to younger and older
premenopausal women, it is common for older premenopausal and younger postmenopausal
women to report vasomotor symptoms.36,37 Similarly, in our study, as premenopausal
women aged, they were 25% to 48% less likely to report vasomotor symptoms. However,
contrary to previous findings,1 as premenopausal women’s age increased, they did not report
higher occurrence rates for vasomotor symptoms. Our sample size may have been too small
to detect the effects of age on the occurrence of hot flashes in our premenopausal women.
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While the occurrence of nighttime awakenings was the most common symptom in both preand postmenopausal women, a significant interaction was found between menopausal status
and age. While no studies evaluated for interaction effects, in previous reports, pre- and
postmenopausal women differed on post-treatment occurrence rates for restless sleep10 and
insomnia.8 Moreover, consistent with prior reports,15 none of the other covariates in the
multivariate analysis predicted variations in the occurrence of wake during the night. Given
the high occurrence rates of nighttime awakenings in women with and without breast cancer,
the causes for this symptom warrant additional investigation so that appropriate
interventions can be prescribed.15
Numbness and tingling are associated with the neurotoxic effects of CTX.38 Therefore, it is
not surprising that women in our study who were treated with CTX in the past 12 months
were 2.5 times more likely to report this symptom. Given that numbness and tingling can be
related to hormonal changes during menopause39 and/or the neurotoxicity of CTX,38 the
etiology of these symptoms warrant evaluation in future studies.
Symptom Severity
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Fatigue was the only symptom that was more severe in premenopausal women and in
women with a higher level of comorbidity. Consistent with a previous report,40
premenopausal women were more likely to report the occurrence as well as more severe
fatigue after CTX and during the first three years of hormone therapy. Given that fatigue is
common, moderately severe, persists over time,19 and may be associated with a higher
symptom burden,41 it warrants ongoing assessment and management.
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While we hypothesized that premenopausal women would report higher severity scores for
vasomotor symptoms, our findings are not consistent with previous reports. In previous
studies, compared to postmenopausal women with breast cancer, premenopausal women
reported more severe vasomotor symptoms15 and hot flashes14 after CTX and were more
likely to report severe hot flashes while taking tamoxifen.25 These inconsistent findings may
be related to differences in how symptoms were assessed and categorized, the timing of the
assessments, and failure to control for significant covariates in the analyses.
The ranking of the five most severe symptoms differed by menopausal group. Moreover,
regardless of menopausal status, the ten most severe symptoms were in the moderate
severity range. In fact, for the entire sample, using a moderate cutoff score of >4.0,42 13 of
the 46 symptoms were in the moderate to severe range. A survivorship care plan, that
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includes aggressive symptom management interventions, is warranted after surgery to
prevent the escalation of symptoms during the subsequent year.
Symptom Distress
No between group differences in symptom distress scores were identified. In contrast,
previous reports suggested that younger women were more bothered by menopausal
symptoms than older women.21,43–45 For example, compared to women older than 60,
younger women reported that vasomotor symptoms, vaginal symptoms, and weight
problems were more bothersome.21 However, the influence of menopausal status was not
evaluated in this study.
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In our study, the analysis of severity and distress ratings included only those women who
reported the occurrence of the symptom. The exclusion of women who did not experience
the symptom provides a more accurate evaluation of the impact of each symptom.3 However,
in most of the previous studies, the analyses included women who did not have the
symptom. In addition, one of the most common instruments used to evaluate menopausalrelated symptoms in breast cancer patients is the Breast Cancer Prevention Trial (BCPT)
checklist.4,46 The BCPT assesses “bother” using a 0 “not at all” to 4 “extremely” Likert
scale. While this instrument is valid and reliable,46 the term “bother” is used interchangeably
with “severity”,10,21 “intensity”,47 and “distress”.48 These differences make comparisons of
severity and distress scores across studies difficult.
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Similar to severity, the rankings of the five most distressing symptoms differed by
menopausal status. Regardless of menopausal status, many of the ten most distressing
symptoms were in the moderate range. While both menopausal groups reported
approximately 11 symptoms, premenopausal women reported a higher number of distressing
symptoms. This difference highlights the importance of comprehensive assessments of all
symptom dimensions in women after breast cancer treatment.
Limitations
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Several limitations warrant consideration. The woman’s self-report of menopausal status at
diagnosis was used to create the two groups. Moreover, the inclusion of five women who
were on HRT in the premenopausal group suggests that some women may have been
perimenopausal. While the gold standard for determining menopausal status includes an
assessment of menstrual cycle, hormonal levels, and symptoms,49 previous studies support
the validity and reliability of self-report.18,50 Moreover, while menopausal status was not reevaluated at 12 months, this study’s aim was to compare pre-surgical menopausal status and
women’s symptom experience at 12 months after surgery. In addition, testing for
interactions between age and menopausal status accounted for variations between younger
and older pre- and postmenopausal women. Some of the symptoms on the MSS (e.g.,
cramps) may be interpreted differently by pre- (i.e., menstrual cramps) versus post- (i.e.,
gastrointestinal cramps) menopausal women. Lastly, the majority of women in this study
was Caucasian and well educated, which limits the generalizability of our findings.
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Implications for Clinical Practice and Research
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Regardless of menopausal status, at one year following surgery, our patients experienced
multiple co-occurring symptoms that were in the moderate to severe range for both severity
and distress. Moreover, similar to previous reports of women after breast cancer treatment,
2,10,11 the occurrence of menopausal-related symptoms varied based on menopausal status,
as well as demographic (e.g., age), clinical (e.g., level of comorbidity), and treatment (e.g.,
prior HRT use, receipt of adjuvant CTX in prior 12 months) characteristics. Of note, all of
the differences in symptom occurrence rates depended on the interaction between age and
menopausal status. Accordingly, both characteristics warrant consideration during the
assessment of symptom burden. Given that these menopausal symptoms negatively impact
women’s well-being after primary breast cancer treatment, assessment and education prior
to and during therapy may help manage expectations of symptom burden over time. Findings
from this study can be used by clinicians to focus their assessments and individualize patient
education and interventions.
Given the various etiologies for menopausal-related symptoms, longitudinal evaluations of
how symptoms change from pre- to post-treatment are warranted. These time-sensitive
evaluations may identify other causal associations between menopausal status and symptom
burden (e.g., pre-surgical anxiety). Moreover, studies of the inter-relationships among
symptoms (i.e., symptom clusters) using multiple dimensions of the symptom experience are
warranted. Increased information on menopausal symptom clusters could be used to support
future studies on the common and distinct mechanisms that underlie these symptom clusters,
well as interventions to manage single and multiple menopausal-related symptoms.
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Refer to Web version on PubMed Central for supplementary material.
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Table 1

Author Manuscript

Differences in demographic and clinical characteristics between premenopausal and postmenopausal women
12 months after breast cancer surgery
Demographic characteristics

Premenopausal
n=115 (35.2%)

Postmenopausal
n=212 (64.8%)

Mean (SD)

Mean (SD)

Age (years)

45.2 (6.2)

61.0 (10.4)

t=−17.21; p<.001

Education (years)

15.9 (2.4)

15.6 (2.8)

t=1.04; p=.296

% (n)

% (n)

White

63.5 (73)

68.9 (146)

Non-white

36.5 (42)

31.1 (66)

Lives alone (% yes)

13.9 (16)

28.4 (60)

FE; p=.004

Married/partnered (% yes)

35.7 (41)

44.8 (95)

FE; p=.127

Currently working for pay (% yes)

60.5 (69)

44.5 (94)

FE; p=.007

6.9 (7)

5.4 (9)

$20,000 to $99,000

47.5 (48)

59.9 (100)

≥ $100,000

45.5 (46)

34.7 (58)

Clinical characteristics

Mean (SD)

Mean (SD)

Body mass index (kg/m2)

25.9 (5.6)

27.1 (6.1)

t=−1.82; p=.069

Karnofsky Performance Status score

94.2 (9.8)

93.6 (10.0)

t=0.50; p=.620

Self-Administered Comorbidity Scale score

3.1 (2.2)

4.4 (3.4)

t=−4.02; p<.001

Number of menopausal symptoms

12.0 (8.7)

10.3 (8.0)

t=1.83; p=.068

Months since diagnosis

13.6 (2.9)

13.8 (2.3)

t=−0.52; p=.601

% (n)

% (n)

Statistics

Ethnicity
FE; p=.328

Author Manuscript

Total annual household income
< $10,000 to $19,999

U; p=.150

Author Manuscript

Occurrence of comorbid conditions (% and number of women who reported each
comorbid condition from the Self-Administered Comorbidity Questionnaire)
Heart disease

Author Manuscript

High blood pressure

1.7 (2)

5.7 (12)

FE; p=.150

14.8 (17)

38.7 (81)

FE; p<.001

Lung disease

1.7 (2)

2.4 (5)

FE; p=1.000

Diabetes

1.7 (2)

12.7 (27)

FE; p<.001

Ulcer

0.0 (0)

5.2 (11)

FE; p=.010

Kidney disease

0.0 (0)

0.0 (0)

FE; p=1.00

Liver disease

0.0 (0)

1.9 (4)

FE; p=.302
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Demographic characteristics

Author Manuscript

Anemia

Premenopausal
n=115 (35.2%)

Postmenopausal
n=212 (64.8%)

Mean (SD)

Mean (SD)

Statistics

Author Manuscript
Author Manuscript

5.2 (6)

4.3 (9)

FE; p=.783

13.0 (15)

16.5 (35)

FE; p=.427

Osteoarthritis

9.6 (11)

22.2 (47)

FE; p=.004

Back pain

22.6 (26)

24.1 (51)

FE; p=.787

3.5 (4)

5.2 (11)

FE; p=.588

Diagnosed with mastitis (% yes)

13.0 (15)

12.7 (27)

FE; p=1.000

Diagnosed with fibrocystic disease (% yes)

15.8 (18)

23.4 (48)

FE; p=.115

Exercise on a regular basis (% yes)

77.4 (89)

73.5 (155)

FE; p=.525

Ever breast fed (% yes)

50.4 (58)

43.4 (92)

FE; p=.246

Prior hysterectomy (% yes)

4.3 (5)

17.9 (38)

FE; p<.001

Prior oophorectomy (% yes)

4.3 (5)

13.7 (29)

FE; p=.008

Breast conservation

72.2 (83)

84.4 (179)

X2; p=.009

Mastectomy

27.8 (32)

15.6 (33)

Sentinel lymph node biopsy (% yes)

86.1 (99)

84.0 (178)

FE; p=.748

Axillary lymph node dissection (% yes)

35.1 (40)

31.6 (67)

FE; p=.538

Re-excision or mastectomy during the 12 months (% yes)

33.9 (39)

27.4 (58)

FE; p=.254

Breast reconstruction during the 12 months (% yes)

20.9 (24)

9.0 (19)

FE; p=.003

Received neoadjuvant chemotherapy (% yes)

15.8 (18)

19.8 (42)

FE; p=.454

Received adjuvant chemotherapy during the 12 months (% yes)

42.6 (49)

28.3 (60)

FE; p=.010

Received external beam radiation therapy during the 12 months (% yes)

65.2 (75)

76.9 (163)

FE; p=.027

On hormonal therapy during the 12 months (% yes)

65.2 (75)

62.3 (132)

FE; p=.632

4.4 (5)

24.6 (52)

FE; p<.001

Stage 0

21.6 (25)

18.0 (38)

Stage I

41.4 (48)

39.3 (83)

Stage IIA and IIB

31.9 (37)

35.5 (75)

Stage IIIA, IIIB, IIIC, and IV

5.2 (6)

7.1 (15)

Estrogen receptor positive (% yes)

78.3 (90)

76.8 (162)

FE; p=.784

Progesterone receptor positive (% yes)

77.4 (89)

67.3 (142)

FE; p=.057

Depression

Rheumatoid arthritis

Type of surgery

On HRT prior to surgery (% yes)
Stage of disease

Author Manuscript
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Demographic characteristics

Author Manuscript

Premenopausal
n=115 (35.2%)

Postmenopausal
n=212 (64.8%)

Mean (SD)

Mean (SD)

16.5 (17)

16.9 (32)

Positive

2.6 (3)

1.0 (2)

Negative

18.4 (21)

7.2 (15)

Not done

78.9 (90)

91.9 (192)

HER2/neu receptor positive (% yes)

Statistics

FE; p=1.000

BRCA1 and BRCA2 genetic testing
X2=10.78; p=.004

Abbreviations: BRCA = breast cancer; FE = Fisher’s Exact; HER2/neu = human epidermal growth factor receptor 2; HRT = hormone replacement
therapy; kg = kilogram; m2 = meters squared; SD = standard deviation; U = Mann Whitney U test

Author Manuscript
Author Manuscript
Author Manuscript
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Table 2

Author Manuscript

Differences between premenopausal and postmenopausal women in rankings of symptoms with the highest
occurrence, severity, and distress ratings 12 months after breast cancer surgery
Occurrence Rates
Premenopausal
Rank

Postmenopausal
% of women

Symptom

% of women
Symptom

Author Manuscript

1

Wake during the night

61.7

Wake during the night

63.7

2

Hot flashes

58.3

Joint pain or stiffness

51.9

3

Fatigue or tiredness

54.8

Fatigue or tiredness

50.0

4

Difficulty falling asleep

44.3

Hot flashes

45.3

5

Night sweats

44.3

Waking too early

42.9

6

Impatience

43.5

Difficulty falling asleep

42.0

7

Irritability

41.7

Backache or neckache

35.8

8

Waking too early

41.7

Impatience

34.4

9

Anxiety

40.9

Night sweats

32.5

10

Backache or neckache

40.9

Anxiety

31.6

Severity Rating+
Rank

Symptom

Mean (SD)

Symptom

Mean (SD)

Author Manuscript

1

Cramps

5.1 (2.5)

Lost sexual interest

6.2 (2.6)

2

Diarrhea

5.0 (3.0)

Cramps

4.6 (2.8)

3

Lost sexual interest

4.7 (2.6)

Abdominal bloating

4.6 (2.7)

4

Fatigue or tiredness

4.7 (2.6)

Vaginal dryness

4.6 (2.9)

5

Mood swings

4.5 (2.8)

Hot flashes

4.4 (2.1)

6

Hot flashes

4.4 (2.5)

Night sweats

4.3 (2.0)

7

Headache

4.4 (2.6)

Joint pain or stiffness

4.2 (2.3)

8

Backache or neckache

4.3 (2.9)

Difficulty falling asleep

4.2 (2.6)

9

Daytime sweats

4.3 (2.4)

Daytime sweats

4.2 (1.8)

10

Joint pain or stiffness

4.3 (2.3)

Wake during the night

4.1 (2.5)

Distress Rating++
Rank

Symptom

Mean (SD)

Symptom

Mean (SD)

Author Manuscript

1

Weight gain

5.1 (3.3)

Lost sexual interest

5.6 (3.4)

2

Diarrhea

5.1 (3.8)

Cramps

5.3 (3.3)

3

Swollen hands/feet

4.9 (2.9)

Abdominal bloating

4.8 (3.7)

4

Hostility

4.8 (3.2)

Weight gain

4.4 (3.4)

5

Tearful/crying spells

4.5 (2.9)

Eating more than usual

4.2 (3.1)

6

Anger

4.5 (3.0)

Joint pain or stiffness

4.0 (2.7)

7

Mood swings

4.5 (3.2)

Panic feelings

4.0 (2.3)

8

Anxiety

4.3 (3.0)

Difficulty falling asleep

4.0 (2.8)

9

Headache

4.2 (3.0)

Depression

3.9 (2.9)
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Occurrence Rates
Premenopausal

Author Manuscript

Rank

Postmenopausal
% of women

Symptom
10

% of women
Symptom

Nausea/upset stomach

4.2 (3.0)

Vaginal dryness

3.9 (2.9)

Abbreviation: SD = standard deviation

+

Symptom severity scores ranged from 0 (none) to 10 (intolerable).

++

Symptom distress scores ranged from 0 (not at all distressing) to 10 (very distressing).

Author Manuscript
Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
25.0

17.2

Skin breakout/acne

PRE
(n=115)

7.1

12.3

POST
(n=212)

Occurrence rate %

Eating more than usual

Symptom

SYMPTOM OCCURRENCE

0.85
2.08

Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy

0.71
2.58
1.33
1.06
0.71
1.12
0.73
1.40
1.20

Age (in 5 year increments)
Lives alone
Working for pay
SCQ score
Prior HRT
Adjuvant chemotherapy during 12 months
Radiation therapy during 12 months
Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy

1.00

1.33

Radiation therapy during 12 months

.009

1.30

Adjuvant chemotherapy during 12 months

0.19, 0.79

0.86

Prior HRT

0.39

1.13

SCQ score

Menopausal status*

0.75

Working for pay

0.43

OR

0.72

.004

p-value

Lives alone

0.23, 0.75

CI

p-value

.125

.771

.501

.425

.761

.044

.384

.429

.565

.050
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0.39, 3.68

0.43, 4.59

0.29, 1.86

0.51, 2.45

0.18, 2.69

0.91, 1.24

0.6, 2.92

1.09, 6.1

0.56, 0.89

0.38, 2.66

.745

.577

.514

.786

.610

.450

.480

.031

.003

.999

Overall Model
X2=24.11; p=.007

0.82, 5.27

0.29, 2.49

0.58, 3.01

0.68, 2.47

0.32, 2.28

1.00, 1.26

0.4, 1.42

0.32, 1.62

0.79, 1.14

0.19, 1.00

Overall Model
X2=19.33; p=.036

CI

Adjusted Model

0.95

0.41

OR

Unadjusted Model

LOGISTIC REGRESSION RESULTS

Age (in 5 year increments)

Menopausal status*

Covariate

Results of unadjusted and adjusted logistic regression analyses that evaluated for differences in symptom occurrence rates between premenopausal and
postmenopausal women 12 months after breast cancer surgery

Author Manuscript
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Author Manuscript
37.1

41.7

Irritability

16.5

Weight gain

Hostility

PRE
(n=115)

Author Manuscript
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29.7

24.6

7.1

POST
(n=212)

Occurrence rate %

1.31
1.05

Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy

1.38
1.50
0.82
1.60

Adjuvant chemotherapy during 12 months
Radiation therapy during 12 months
Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy

Age (in 5 year increments)

0.94

0.60

0.64

Prior HRT

.027

1.01

SCQ score

0.36, 0.94

0.99

Working for pay

0.58

0.99

Lives alone

Menopausal status

0.87

Age (in 5 year increments)

0.94

1.54

Radiation therapy during 12 months

.025

0.83

Adjuvant chemotherapy during 12 months

0.35, 0.93

1.56

Prior HRT

0.57

1.09

SCQ score

Menopausal status*

0.85

Working for pay

0.59

OR

0.96

.009

p-value

0.77

0.19, 0.79

CI

p-value

.940

.680

.410

.637

.433

.240

.667

.926

.021

.284

.251

.680

.241

.228

.254

.798

.980

.963

.062

.846

0.82, 1.07

0.32, 1.15

.342

.1 26

Overall Model
X2=12.25; p=.269

0.72, 3.6

0.32, 2.09

0.76, 2.98

0.82, 2.34

0.29, 1.38

0.92, 1.12

0.59, 1.66

0.53, 1.84

0.75, 1.01

0.48, 1.83

Overall Model
X2=17.02; p=.074

0.31, 3.54

0.36, 4.83

0.55, 4.25

0.38.1.82

0.51, 4.75

0.94, 1.26

0.40, 1.80

0.36, 2.52

0.62, 0.96

0.23, 1.54

Overall Model
X2=15.12; p=.128

CI

Adjusted Model

Lives alone

0.38

OR

Unadjusted Model

Age (in 5 year increments)

Menopausal status*

Covariate

Author Manuscript

Symptom

LOGISTIC REGRESSION RESULTS

Author Manuscript

SYMPTOM OCCURRENCE
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22.4

13.7

POST
(n=212)

0.77
0.18
0.92
1.03
1.30
0.99
0.69
1.18
0.61

Age (in 5 year increments)
Lives alone
Working for pay
SCQ score
Prior HRT
Adjuvant chemotherapy during 12 months
Radiation therapy during 12 months
Reconstruction during 12 months
Type of surgery: conservation (ref) or mastectomy

1.18

1.85

Type of surgery: conservation (ref) vs mastectomy

.039

0.78

Reconstruction during 12 months

0.30, 0.98

1.63

Radiation therapy during 12 months

0.54

0.90

Menopausal status*

1.13

Adjuvant chemotherapy during 12 months

1.07

SCQ score
Prior HRT

0.93

OR

Working for pay

p-value
0.98

CI

.117

.588

.140

.684

.714

.144

.769

.939

p-value

0.22, 1.72

0.4, 3.51

0.31, 1.56

0.52, 1.91

0.53, 3.2

0.91, 1.16

0.49, 1.71

0.05, 0.60

0.64, 0.92

0.53, 2.59

.353

.763

.377

.987

.571

.680

.784

.005

.005

.687

Overall Model
X2 =26.27; p=.003

0.86, 4.00

0.32, 1.91

0.85, 3.10

0.54, 1.50

0.58, 2.20

0.98, 1.17

0.57, 1.51

0.55, 1.75

CI

Adjusted Model

Lives alone

OR

Unadjusted Model

reference group = premenopausal women

*

Abbreviations: CI = confidence interval; HRT = hormone replacement therapy; OR = odds ratio; PRE = premenopausal; POST = postmenopausal; ref = reference group; SCQ = Self-administered
Comorbidity Questionnaire; vs = versus

Lost sexual interest

PRE
(n=115)

Occurrence rate %

Covariate

Author Manuscript

Symptom

Author Manuscript
LOGISTIC REGRESSION RESULTS

Author Manuscript

SYMPTOM OCCURRENCE
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Author Manuscript
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Night Sweats
PRE = 44.3%
POST = 32.5%

Hot flashes
PRE = 58.3%
POST = 45.3%

Symptom
CI

p-value

OR

0.65
1.07
2.19
1.11
1.11
1.52
0.96
0.42

SCQ score
Prior HRT
Adjuvant chemotherapy during 12 months
Radiation therapy during 12 months
Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy
Age × menopausal status

0.29, 0.61

0.44, 2.1 0

0.63, 3.68

0.59, 2.1 0

0.66, 1.87

1.1 0, 4.36

0.97, 1.17

0.39, 1.07

0.51, 1.65

1.00, 1.92

136.43, 236576.94

Overall Model
X2=59.53; p<.001

CI

Adjusted Model

1.05
0.97
1.04

Working for pay
SCQ score

1132.50

Lives alone

.026

1.3 0

0.37, 0.94

Age (in 5 year increments)

0.59

0.56

Postmenopausal

Menopausal status*

1.43

Premenopausal

0.95, 1.15

0.59, 1.59

0.57, 1.92

0.94, 1.8 0

29.38, 43655.1

Overall Model
X2=41.70; p<.001

0.46, 0.69

0.99, 2.06

Adjusted Regression of Hot Flashes Occurrence on Age, Stratified by Menopausal Status

0.92

Working for pay

5681.12

Lives alone

.015
1.38

0.35, 0.89

Age (in 5 year increments)

0.56

Logistic Regression Results for Total Sample

OR

Unadjusted Model

LOGISTIC REGRESSION RESULTS

Menopausal status*

Covariates

.397

.892

.872

.117

<.001

<.001

.055

.000

.921

.352

.739

.692

.026

.188

.089

.770

.050

<.001

p-value

Results of unadjusted and adjusted logistic regression analyses that evaluated for differences between premenopausal and postmenopausal women in
symptom occurrence rates with interaction effects 12 months after breast cancer surgery

Author Manuscript
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Daytime sweats
PRE = 39.7%
POST = 26.9%

Depression
PRE = 34.5%
POST = 24.5%

0.91
1.28
0.49

Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy
Age × menopausal status

CI

0.34, 0.71

0.58, 2.82

0.38, 2.2 0

0.45, 1.62

0.62, 1.75

1.18, 4.67

Adjusted Model

1.02
1.18
0.83
1.04
0.82
1.19
1.16
0.54

Working for pay
SCQ score
Prior HRT
Adjuvant chemotherapy during 12 months
Radiation therapy during 12 months
Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy
Age × menopausal status

0.36, 0.8 0

0.51, 2.64

0.47, 2.98

0.42, 1.61

0.60, 1.79

0.39, 1.76

1.07, 1.30

0.60, 1.73

0.47, 1.71

0.98, 2.02

6.92, 16611.16

Overall Model
X2 =30.92; p=.001

0.52, 0.76

0.92, 1.88

0.53

0.33, 0.87

.011

137.20

0.77

Postmenopausal

Menopausal status*

1.50

Premenopausal

3.53, 5329.31

Overall Model
X2=34.535; p=.011

0.64, 0.92

1.00, 2.25

Adjusted Regression of Depression Occurrence on Age, Stratified by Menopausal Status

0.89

338.93

Lives alone

.047

1.41

0.37, 0.99

Age (in 5 year increments)

0.60

0.63

Postmenopausal

Menopausal status*

1.31

Premenopausal

Adjusted Regression of Night Sweats Occurrence on Age, Stratified by Menopausal Status

0.85

Radiation therapy during 12 months

OR

1.04

p-value

Adjuvant chemotherapy during 12 months

CI
2.35

OR

Unadjusted Model

Prior HRT

Covariates

Author Manuscript
Symptom

Author Manuscript

LOGISTIC REGRESSION RESULTS

.008

.003

.048

.002

.725

.717

.571

.889

.620

.001

.937

.733

.061

.003

<.001

.140

<.001

.536

.837

.632

.872

.015

p-value
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Joint pain or stiffness
PRE = 40.0%
POST = 51.9%

1.08
2.92
0.98
1.21
0.62
2.18
0.57

SCQ score
Prior HRT
Adjuvant chemotherapy during 12 months
Radiation therapy during 12 months
Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy
Age × menopausal status

CI

0.39, 0.83

0.97, 4.93

0.24, 1.56

0.61, 2.39

0.57, 1.66

1.46, 5.83

0.98, 1.19

0.54, 1.51

0.42, 1.47

0.93, 1.83

Adjusted Model

Author Manuscript

Author Manuscript
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0.89
1.07
1.00
1.40
0.63
1.31
0.61
0.54

Working for pay
SCQ score
Prior HRT
Adjuvant chemotherapy during 12 months
Radiation therapy during 12 months
Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy
Age × menopausal status

0.36, 0.83

0.28, 1.31

0.54, 3.16

0.34, 1.17

0.85, 2.32

0.54, 1.86

0.98, 1.17

0.55, 1.42

0.56, 1.68

1.26, 2.79

6.64, 22601.80

Overall Model
X2=23.66; p=.014

0.63, 0.89

0.89, 1.81

Adjusted Regression of Joint Pain Occurrence on Age, Stratified by Menopausal Status

0.97

387.32

Lives alone

.043

1.88

1.02, 2.57

Age (in 5 year increments)

1.62

0.74

Postmenopausal

Menopausal status*

1.27

Premenopausal

.004

.206

.551

.145

.188

.993

.133

.614

.906

.002

.004

.001

.190

.004

.060

.308

.581

.931

.002

.122

.705

.446

.121

p-value

Adjusted Regression of Daytime Sweats Occurrence on Age, Stratified by Menopausal Status

0.91

Working for pay

OR

0.78

p-value

Lives alone

CI
1.3 0

OR

Unadjusted Model

Age (in 5 year increments)

Covariates

Author Manuscript
Symptom

Author Manuscript
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Numbness or tingling
PRE = 27.8%
POST = 29.7%

Wake during the night
PRE = 61.7%
POST = 63.7%

0.64
1.10
1.29
0.90
1.06
2.53
0.7 0
0.62

Working for pay
SCQ score
Prior HRT
Adjuvant chemotherapy during 12 months
Radiation therapy during 12 months
Reconstruction during 12 months
Type of surgery: conservation (ref) vs mastectomy
Age × menopausal status

0.86, 1.15

1.33, 3.23

0.44, 0.88

0.32, 1.54

0.99, 6.47

0.57, 1.97

0.53, 1.51

0.67, 2.48

1.00, 1.21

0.39, 1.05

0.52, 1.63

0.91, 1.72

4.59, 4893.95

Overall Model
X2=23.12; p=.017

CI

Adjusted Model

.008

.380

.052

.855

.678

.447

.058

.079

.779

.170

.005

.947

.001

p-value

Author Manuscript

Author Manuscript
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1.52
0.74
1.08
1.05
2.47
0.82

Working for pay
SCQ score
Prior HRT
Adjuvant chemotherapy during 12 months
Radiation therapy during 12 months

174.64

Lives alone

.673

1.29

0.67, 1.86
Age (in 5 year increments)

1.12

0.76

Postmenopausal

Menopausal status*

1.29

Premenopausal

0.42, 1.6 0

1.45, 4.20

0.52, 2.12

0.98, 1.18

0.44, 1.24

0.83, 2.79

0.89, 1.87

3.33, 9171.79

Overall Model
X2=29.37; p=.002

0.64, 0.90

0.92, 1.80

.562

.001

.900

.143

.253

.174

.185

.011

.001

.142

Adjusted Regression of Wake During the Night Occurrence on Age, Stratified by Menopausal Status

0.92

149.89

Lives alone

.764
1.25

0.67, 1.73

Age (in 5 year increments)

Menopausal status*
1.08

OR

1.00

p-value

Postmenopausal

CI
2.07

OR

Unadjusted Model

Premenopausal

Covariates

Author Manuscript
Symptom

Author Manuscript

LOGISTIC REGRESSION RESULTS
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Author Manuscript
CI

0.41, 0.92

0.52, 2.6 0

0.42, 2.67

Adjusted Model

.019

.710

.905

p-value

Author Manuscript
0.79

Postmenopausal

0.66, 0.93

0.88, 1.98
.006

.176

reference group = premenopausal women

*

Abbreviations: CI = confidence interval; HRT = hormone replacement therapy; OR = odds ratio; PRE = premenopausal; POST = postmenopausal; ref = reference group; SCQ = Self-administered
Comorbidity Questionnaire; vs = versus

1.32

Premenopausal

Adjusted Regression of Numbness or Tingling Occurrence on Age, Stratified by Menopausal Status

0.62

Age × menopausal status

OR

1.16

p-value

Type of surgery: conservation (ref) vs mastectomy

CI
1.06

OR

Unadjusted Model

Reconstruction during 12 months

Covariates

Author Manuscript

Symptom

Author Manuscript

LOGISTIC REGRESSION RESULTS
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Author Manuscript

Author Manuscript

Author Manuscript

4.7 (2.6)

3.8 (2.3)

Impatience

Premen

2.7 (1.8)

3.8 (2.4)

Postmen

Severity Score (0–10)
Mean (SD)

SYMPTOM

Fatigue

Symptom
B

CI

−1.51, 0.06

.071

−1.00

0.40
0.50
−0.24
−0.30

Prior HRT
Any adjuvant chemotherapy in past 12 months
Any adjuvant radiation therapy in past 12 months
Any breast reconstructions months in past 12 months
Type of surgery: lumpectomy (ref) vs mastectomy

−0.12
−0.31
−0.18
0.14
−0.12
0.66
0.20
0.66

Lives alone
Working for pay
SCQ score
Prior HRT
Any adjuvant chemotherapy in past 12 months
Any adjuvant radiation therapy in past 12 months
Any breast reconstructions months in past 12 months

−0.89

Age (in 5 year increments)

.002

0.29

SCQ score

−1.88, −0.42

0.19

Working for pay

−1.15

p-value

−1.47, 0.88

−1.58, 1.11

−0.43, 1.44

−0.42, 1.23

−0.74, 1.31

0.05, 0.34

−1.35, 0.19

−0.55, 1.27

−0.36, 0.06

−1.98, −0.01

.616

.729

.290

.336

.580

.008

.140

.437

.163

.048
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−0.63, 1.95

−0.74, 1.14

−0.11, 1.43

−1.16, 0.92

−0.01, 0.29

−0.92, 0.56

−1.20, 0.58

−0.30, 0.07

−1.80, 0.02

.313

.678

.091

.816

.061

.639

.486

.227

.055

Overall Model
F=2.22; R2=.17; p=.022

0.36
−0.58

Lives alone

Menopausal status*

CI

Adjusted Model

Overall Model
F=2.11; R2=.12; p=.027

−0.15

−0.73

B

Age (in 5 year increments)

Menopausal status*

p-value

Unadjusted Model

LINEAR REGRESSION RESULTS

SYMPTOM SEVERITY

Covariate

Results of unadjusted and adjusted linear regression analyses that evaluated for differences in symptom severity and distress scores between
premenopausal and postmenopausal women 12 months after surgery

Author Manuscript
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Author Manuscript
Impatience

Symptom

Irritability

2.9 (1.9)

Postmen

3.9 (2.9)

PRE
2.6 (2.0)

POST

Distress Score (0–10)
Mean (SD)

3.8 (2.4)

Premen

Severity Score (0–10)
Mean (SD)
B

CI

p-value

Unadjusted Model

Any breast reconstructions months in past 12 months
Type of surgery: lumpectomy (ref) vs mastectomy

−0.28
0.14
−0.6 0
0.53
−0.09
0.65

Working for pay
SCQ score
Prior HRT
Any adjuvant chemotherapy in past 12 months
Any adjuvant radiation therapy in past 12 months
Any breast reconstructions months in past 12 months

−0.69

−0.59

.005

−0.18

−2.17, −0.40

p-value

Lives alone

−1.29

CI

Age (in 5 year increments)

Menopausal status*

B

Unadjusted Model

.194

p-value

CI

Adjusted Model

−1.4, 0.75

−0.45, 2.17

−0.70, 1.22

−0.17, 1.48

−1.17, 1.01

0.14, 0.45

−1.09, 0.47

−0.81, 1.03

−0.52, −0.12

−1.46, 0.34

p-value

.551

.194

.596

.119

.888

<.001

.428

.814

.002

.219
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−0.92, 2.22

−1.25, 1.08

−0.41, 1.46

−1.87, 0.68

−0.04, 0.32

−1.18, 0.61

−1.68, 0.50

−0.42, 0.05

−1.79, 0.41

.413

.884

.266

.354

.134

.532

.283

.131

.217

Overall Model
F=2.01; R2=.15; p=.039

0.86
−0.32

Any adjuvant radiation therapy in past 12 months

B

0.26

Any adjuvant chemotherapy in past 12 months

Covariate

0.66

Prior HRT

SYMPTOM DISTRESS

0.29
−0.08

SCQ score

−0.31

Working for pay

−0.56

0.11

.008

Lives alone

−1.91, −0.30

−1.90, 0.39

CI

Adjusted Model

Overall Model
F=3.81; R2=.28; p<.001

−0.32

−1.10

B
−0.76

Age (in 5 year increments)

Menopausal status*

Type of surgery: lumpectomy (ref) vs mastectomy

Covariate

Author Manuscript

Symptom

LINEAR REGRESSION RESULTS

Author Manuscript

SYMPTOM
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Author Manuscript
Postmen

B

CI

p-value

Unadjusted Model

Type of surgery: lumpectomy (ref) vs mastectomy

Covariate
B
−0.65

−2.05, 0.75

CI

Adjusted Model

.36 0

p-value

reference group = premenopausal women

*

Abbreviations: B = Beta coefficient; CI = confidence interval; HRT = hormone replacement therapy; Premen = premenopausal; Postmen = postmenopausal; ref = reference group; SCQ = Self-administered
Comorbidity Questionnaire; vs = versus

Premen

Severity Score (0–10)
Mean (SD)

Author Manuscript

Symptom

Author Manuscript

LINEAR REGRESSION RESULTS

Author Manuscript

SYMPTOM
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